The European Heart Rhythm Association (EHRA) updated its practical guide on use of non-vitamin K antagonist oral anticoagulants in specific clinical situations and particular patient groups.
Defining statin eligibility based on the predicted CV benefit, rather than the absolute CV risk, shifts statin eligibility to more intermediate CV risk subjects.
In a large, prospective, population-based cohort, the waist-to-hip ratio was more strongly associated with the risk of MI compared with BMI, especially in women.
New data of the ongoing GLORIA-AF registry on use of dabigatran in AF show low rates of major bleeding and stroke, and long-term safety data are consistent with other real-world and RCT evidence.
Maintaining or increasing physical activity was associated with substantial reductions in CVD mortality risk, in a large cohort of patients with angina pectoris or myocardial infarction.
EPCCS Council Already at the second Council meeting, we shift gears from making plans to taking action and bringing the support of the European Primary Cardiovascular Care Community to a higher level.
ACC 2018 Treatment with alirocumab on top of high-intensity statins lowered MACE by 15% in patients with recent ACS in the ODYSSEY OUTCOMES trial and was associated with a lower rate of all-cause death.
ACC 2018 In the digital mSToPS trial using patient-generated data, a wearable ECG patch improved the rate of AF diagnosis at 1 year compared to routine care.
ACC 2018 In post-MI patients with a low LVEF, WCD reduced total mortality in the immediate post-MI period (<90 days), but not sudden cardiac death.
ACC 2018 Treatment with canakinumab reduced MACE+ in patients with CKD in the CANTOS trial, with a stronger reduction in those who achieved on-treatment hsCRP<2 mg/mL compared to >2 mg/mL.
In a data-driven cluster analysis of 6 variables in adult patients with newly diagnosed diabetes, 5 categories of patients were identified with different characteristics and risks of complications.
Overweight and obese individuals have a significantly increased long-term risk for CVD morbidity, and a similar or shorter total longevity, compared with individuals with a normal BMI.